Abstract
Background: Supplementary insulin therapy provides assistance to meal-time insulin secretion in patients with type 2 diabetes and may have protective effects on β-cell function.
Methods: This study explored the immediate effect of supplementary insulin therapy on β- cell function in patients with glimepiride monotherapy (five women, 15 men; 61.8 ± 6.4 years old; body mass index, 31.1 ± 4.4 kg/m2; hemoglobin A1c, 7.0 ± 1.3%). After 1 week of continued glimiperide therapy, the patients were randomized either to continue with their oral treatment or to switch to a fixed-dose supplementary insulin therapy (8 U of insulin aspart subcutaneously before each meal) for another week. Oral glucose tolerance tests (OGTTs) after drug uptake were performed at days 7 and 14, with measurement of glucose, insulin, C-peptide, intact and total proinsulin, glucagon, lactate, free fatty acids, and adiponectin.
Results: Significant reductions from baseline were seen in the supplementary insulin therapy group for the fasting values of insulin (from 13.1 ± 5.1 µU/mL to 10.6 ± 5.2 µU/mL, P < 0.01), intact proinsulin (from 18.3 ± 11.2 pmol/L to 10.3 ± 4.6 pmol/L, P µ 0.05), total proinsulin (from 43.3 ± 22.7 pmol/L to 29.7 ± 14.5 pmol/L, P < 0.01), split proinsulin (from 24.9 ± 13.8 pmol/L to 19.4 ± 10.8 pmol/L, P µ 0.01), and the degree of β-cell dysfunction (P < 0.05). Also, lower values for intact and total proinsulin and split proinsulin in the OGTT were observed in this group during the OGTT at the end point, while no changes at all occurred in the glimepiride group.
Conclusions: A fixed low-dose preprandial insulin aspart therapy resulted in an overall β-cell protection with an improved fasting β-cell secretion profile already within 1 week. Our study indicates that supplementary insulin therapy might be a reasonable alternative to bedtime basal insulin injections for initiation of insulin therapy in patients with type 2 diabetes.
Get full access to this article
View all access options for this article.